Genome-wide DNA methylation signatures to predict pathologic complete response from combined neoadjuvant chemotherapy with bevacizumab in breast cancer.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 32298288.
- Also identified by DOI 10.1371/journal.pone.0230248 and PMC identifier 7162481.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
ClinicalTrials.gov Identifier: NCT00203502.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
- DNA Methylation
- DNA, Neoplasm
- Neoadjuvant Therapy
- Promoter Regions, Genetic